Federated Learning Enables Big Data for Rare Cancer Boundary Detection
Authors:
Sarthak Pati,
Ujjwal Baid,
Brandon Edwards,
Micah Sheller,
Shih-Han Wang,
G Anthony Reina,
Patrick Foley,
Alexey Gruzdev,
Deepthi Karkada,
Christos Davatzikos,
Chiharu Sako,
Satyam Ghodasara,
Michel Bilello,
Suyash Mohan,
Philipp Vollmuth,
Gianluca Brugnara,
Chandrakanth J Preetha,
Felix Sahm,
Klaus Maier-Hein,
Maximilian Zenk,
Martin Bendszus,
Wolfgang Wick,
Evan Calabrese,
Jeffrey Rudie,
Javier Villanueva-Meyer
, et al. (254 additional authors not shown)
Abstract:
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train acc…
▽ More
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here we present findings from the largest FL study to-date, involving data from 71 healthcare institutions across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, utilizing the largest dataset of such patients ever used in the literature (25,256 MRI scans from 6,314 patients). We demonstrate a 33% improvement over a publicly trained model to delineate the surgically targetable tumor, and 23% improvement over the tumor's entire extent. We anticipate our study to: 1) enable more studies in healthcare informed by large and diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further quantitative analyses for glioblastoma via performance optimization of our consensus model for eventual public release, and 3) demonstrate the effectiveness of FL at such scale and task complexity as a paradigm shift for multi-site collaborations, alleviating the need for data sharing.
△ Less
Submitted 25 April, 2022; v1 submitted 22 April, 2022;
originally announced April 2022.
